New chemo combo shows promise in early breast cancer trial
NCT ID NCT06513364
First seen Jan 27, 2026 · Last updated May 13, 2026 · Updated 12 times
Summary
This study tested a new drug called WH002 against the standard chemotherapy paclitaxel in 40 women with HER2-negative breast cancer. Both drugs were given before surgery, followed by epirubicin and cyclophosphamide. The main goal was to check safety and side effects, and also to see how well the drugs shrank tumors. The trial has completed, and results will help decide if WH002 is a good alternative to paclitaxel.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, Beijing Municipality, 100021, China
Conditions
Explore the condition pages connected to this study.